On behalf of the Hooper, Lundy & Bookman’s Health Equity Task Force, here is our most recent HLB Health Equity Essentials Update. On other reproductive law fronts, two forthcoming SCOTUS opinions could stand to have wide-reaching repercussions. One is FDA v. Alliance for Hippocratic Medicine, which will decide whether mifepristone – one of two FDA-approved medication abortion drugs – remains readily available in the U.S. The other, Moyle v. United States, will determine whether EMTALA’s requirement to provide “necessarily stabilizing treatment” preempts an Idaho law, in the emergency context, that bans most abortions. If you have any questions, please reach out to Alicia Macklin, Sandi Krul, Monica Massaro, Kerry Sakimoto, or your regular HLB contact.
Professional